Tag: Aminoacridine acetylcholinesterase inhibitor

  • Tacrine

    Aminoacridine acetylcholinesterase inhibitor

    The first FDA-approved Alzheimer disease therapy (1993), withdrawn for hepatotoxicity but historically important and retained as a research probe.

    Abstract

    Tacrine (Cognex, 1,2,3,4-tetrahydroacridin-9-amine; CAS 321-64-2; molecular formula C13H14N2; molecular weight 198.27) is the first FDA-approved cholinesterase inhibitor for Alzheimer disease, granted approval in 1993 and subsequently withdrawn from the US market in 2013 due to hepatotoxicity (approximately 50 percent of patients developed clinically significant ALT elevation requiring monitoring or discontinuation). The compound is a non-selective reversible AChE and BChE inhibitor based on an aminoacridine scaffold. Mechanism includes additional weak NMDA receptor antagonism and modest sodium channel blockade, distinguishing the pharmacology from the more selective subsequent AChE inhibitors. The historical significance of tacrine is substantial; the compound established cholinesterase inhibition as a viable therapeutic strategy for Alzheimer disease and led to development of the more tolerable second-generation agents. The compound retains research utility as a pharmacological probe and AChE reference compound. Pharmacokinetics: short half-life (3 to 4 hours), four-times-daily dosing required in the marketed formulation. Hepatotoxicity is dose-related and reversible on discontinuation in most cases.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.